NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Forecast, Price & News $1.45 -0.11 (-7.05%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$1.44▼$1.5850-Day Range$1.45▼$3.3552-Week Range$1.44▼$8.25Volume707,604 shsAverage Volume800,407 shsMarket Capitalization$363.99 millionP/E RatioN/ADividend YieldN/APrice Target$6.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lyell Immunopharma MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside331.0% Upside$6.25 Price TargetShort InterestBearish18.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.08) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector727th out of 961 stocksPharmaceutical Preparations Industry341st out of 454 stocks 3.1 Analyst's Opinion Consensus RatingLyell Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Lyell Immunopharma has a forecasted upside of 331.0% from its current price of $1.45.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.27% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 24.3, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 3.67%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYEL. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders24.00% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.67% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($1.08) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lyell Immunopharma (NASDAQ:LYEL) StockLyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.Read More LYEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYEL Stock News HeadlinesSeptember 11, 2023 | marketwatch.comLyell Immunopharma Shares Up 8% on Cellares CollaborationSeptember 11, 2023 | finance.yahoo.comCellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 31, 2023 | finance.yahoo.comLyell Immunopharma to Participate in Upcoming Investor ConferencesAugust 29, 2023 | finance.yahoo.comAnalysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging HigherAugust 28, 2023 | msn.comJP Morgan cuts Lyell to neutral, pending data for cell therapy platformAugust 28, 2023 | msn.comJP Morgan Downgrades Lyell Immunopharma (LYEL)August 26, 2023 | msn.comLyell Immunopharma: Once Huge IPO Now Waiting For Clinical DataSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 9, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Lyell Immunopharma (LYEL)August 8, 2023 | finance.yahoo.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023July 6, 2023 | lse.co.ukMaxCyte inks strategic platform license with Lyell ImmunopharmaJuly 6, 2023 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Lyell ImmunopharmaJuly 5, 2023 | finance.yahoo.comLyell Immunopharma Appoints Matthew Lang as Chief Business OfficerJune 16, 2023 | finance.yahoo.comWhy Shares of Lyell Immunopharma Jumped This WeekJune 7, 2023 | finance.yahoo.comLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceJune 1, 2023 | finance.yahoo.comEven after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down 31% over the past yearMay 5, 2023 | msn.comHC Wainwright & Co. Reiterates Lyell Immunopharma (LYEL) Buy RecommendationMay 5, 2023 | markets.businessinsider.comLyell Immunopharma (LYEL) Receives a Buy from H.C. WainwrightMay 4, 2023 | finance.yahoo.comLyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2023 | msn.comLyell Immunopharma reports Q1 resultsMay 4, 2023 | finance.yahoo.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023April 17, 2023 | finance.yahoo.comThere's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted RevenuesApril 13, 2023 | benzinga.comTORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology BiologicsMarch 27, 2023 | finance.yahoo.comAurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?March 26, 2023 | finance.yahoo.comLyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stakeMarch 1, 2023 | finanznachrichten.deLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022See More Headlines Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Company Calendar Last Earnings8/08/2023Today9/21/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LYEL CUSIPN/A CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees274Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.25 High Stock Price Forecast$9.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+331.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-183,120,000.00 Net Margins-432.13% Pretax Margin-432.13% Return on Equity-26.40% Return on Assets-23.08% Debt Debt-to-Equity RatioN/A Current Ratio17.63 Quick Ratio17.63 Sales & Book Value Annual Sales$84.68 million Price / Sales4.30 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.43Miscellaneous Outstanding Shares251,030,000Free Float190,781,000Market Cap$363.99 million OptionableNot Optionable Beta-1.38 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Richard D. Klausner M.D. (Age 71)Founder & Exec. Chairman Comp: $80kDr. Lynn Seely M.D. (Age 64)Ph.D., Pres, CEO & Director Comp: $430.69kMr. Charles W. Newton (Age 52)Chief Financial Officer Comp: $1.72MMr. Stephen J. Hill (Age 53)Chief Operating Officer Comp: $1.04MDr. Gary Lee Ph.D. (Age 46)Chief Scientific Officer Comp: $639.91kMs. Elizabeth Homans (Age 57)Consultant Comp: $1.99MProf. Stanley R. Riddell M.D.Founder & Scientific AdvisorDr. Crystal L. Mackall M.D.Founder & Scientific AdvisorNellie DilleryDirector of AccountingMs. Ellen RoseSr. VP of Communications & Investor RelationsMore ExecutivesKey CompetitorsEdgewise TherapeuticsNASDAQ:EWTXCOMPASS PathwaysNASDAQ:CMPSUroGen PharmaNASDAQ:URGNArcutis BiotherapeuticsNASDAQ:ARQTAldeyra TherapeuticsNASDAQ:ALDXView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 103,178 shares on 8/21/2023Ownership: 0.067%Nuveen Asset Management LLCBought 143,569 shares on 8/16/2023Ownership: 0.235%Wells Fargo & Company MNBought 5,919 shares on 8/15/2023Ownership: 0.048%Royal Bank of CanadaBought 8,424 shares on 8/15/2023Ownership: 0.007%Citadel Advisors LLCBought 200 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LYEL Stock - Frequently Asked Questions Should I buy or sell Lyell Immunopharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares. View LYEL analyst ratings or view top-rated stocks. What is Lyell Immunopharma's stock price forecast for 2023? 4 brokerages have issued 1 year price targets for Lyell Immunopharma's shares. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 331.0% from the stock's current price. View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts. How have LYEL shares performed in 2023? Lyell Immunopharma's stock was trading at $3.47 at the start of the year. Since then, LYEL shares have decreased by 58.2% and is now trading at $1.45. View the best growth stocks for 2023 here. When is Lyell Immunopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our LYEL earnings forecast. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.31 million. Lyell Immunopharma had a negative net margin of 432.13% and a negative trailing twelve-month return on equity of 26.40%. When did Lyell Immunopharma IPO? (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO. What is Lyell Immunopharma's stock symbol? Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL." Who are Lyell Immunopharma's major shareholders? Lyell Immunopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.21%), Foresite Capital Management IV LLC (3.86%), State Street Corp (2.46%), Geode Capital Management LLC (1.34%), Northern Trust Corp (0.57%) and Charles Schwab Investment Management Inc. (0.46%). Insiders that own company stock include Cathy Friedman and Richard Klausner. View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lyell Immunopharma's stock price today? One share of LYEL stock can currently be purchased for approximately $1.45. How much money does Lyell Immunopharma make? Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $363.99 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How many employees does Lyell Immunopharma have? The company employs 274 workers across the globe. How can I contact Lyell Immunopharma? The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com. This page (NASDAQ:LYEL) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.